Prelude Therapeutics Net Cash Flow 2020-2025 | PRLD

Prelude Therapeutics net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

Prelude Therapeutics Net Cash Flow 2020-2025 | PRLD

Prelude Therapeutics net cash flow from 2020 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$81.7B
Zoetis (ZTS)$67.1B
Daiichi Sankyo, - (DSNKY)$46.4B
Takeda Pharmaceutical (TAK)$45.5B
BeOne Medicines - (ONC)$32.3B
Sandoz Group AG (SDZNY)$26.1B
Summit Therapeutics (SMMT)$20.4B
Merck (MKKGY)$16.9B
Shionogi (SGIOY)$15B
United Therapeutics (UTHR)$13.4B
Neurocrine Biosciences (NBIX)$13.2B
Orion OYJ (ORINY)$11.5B
IPSEN (IPSEY)$10.8B
Stevanato Group S.p.A (STVN)$7.9B
Corcept Therapeutics (CORT)$7.3B
Grifols, S.A (GRFS)$6.9B
Ionis Pharmaceuticals (IONS)$6.6B
Madrigal Pharmaceuticals (MDGL)$6.5B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.3B
Hypermarcas (HYPMY)$3B
Crinetics Pharmaceuticals (CRNX)$2.8B
NewAmsterdam Pharma (NAMS)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2B
Ocular Therapeutix (OCUL)$1.9B
Endo (NDOI)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B